Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory biomarker study for diagnosis and treatment monitoring of pulmonary tuberculosis
2025-522235-34-00Phase 4Completed
- Sponsor
- FIBHULP
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isoniazid, rifampicin, pyrazinamide and ethambutol in pulmonary tuberculosis (TB) (2 arms), sponsored by FIBHULP. Started Feb 2026; status: completed.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2025-522235-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522235-34-00.